Nektar Therapeutics | NKTR - 流动资产



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 15.95B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


流动资产 更改 日
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
ALKERMES USD 1.36B 570.52M 2026-03
Alterity Therapeutics Limited AUD 37.91M 15.92M 2025-12
Amgen USD 31.48B 2.42B 2026-03
Baxter International USD 6.85B 25M 2026-03
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Biogen USD 9.19B 216.3M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Cara Therapeutics USD 38.44M 4.69M 2025-09
Cipla INR 249.18B 16.3B 2025-09
Dr.Reddys Laboratories INR 297.55B 18.03B 2025-12
Eisai JPY 840.88B 50.18B 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Exelixis USD 1.44B 41.03M 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
GlaxoSmithKline GBP 17.76B 251M 2026-03
Grifols EUR 5.96B 316.31M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Ironwood Pharmaceuticals USD 273.84M 82.09M 2025-09
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
Merck USD 35.02B 8.5B 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novartis USD 26.61B 3.85B 2026-03
Pfizer USD 42.82B 76M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Takeda JPY 3.12T 195.82B 2025-12
Teva Pharmaceutical Industries USD 13.71B 236M 2026-03
Xencor USD 599.82M 81.38M 2025-12